MONTGOMERY, Texas--(BUSINESS WIRE)--AngioSoma, Inc. (OTCQB:SOAN) (the ‘Company,’ ‘we,’ and ‘our’), announces the formation of its scientific advisory board with the addition of A. Tomas Garcia III, MD, a practicing physician in the field of cardiology for the past 35 years and the immediate past president of the Texas Medical Association. Dr. Garcia’s longstanding association with our Chairman Emeritus and insight into the Company’s flagship product Liprostin™ allows Dr. Garcia to immediately make a significant impact on our progress towards U.S. Food and Drug Administration (‘FDA’) Phase III trials of Liprostin™.
